- Home
- IBRX vs VYX Comparison
IBRX vs VYX Comparison
Compare IBRX & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- VYX
- Stock Information
- Founded
- IBRX 2014
- VYX 1881
- Country
- IBRX United States
- VYX United States
- Employees
- IBRX N/A
- VYX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- VYX
- Sector
- IBRX Health Care
- VYX
- Exchange
- IBRX Nasdaq
- VYX Nasdaq
- Market Cap
- IBRX 1.9B
- VYX 2.1B
- IPO Year
- IBRX N/A
- VYX N/A
- Fundamental
- Price
- IBRX $2.94
- VYX $13.11
- Analyst Decision
- IBRX Strong Buy
- VYX Strong Buy
- Analyst Count
- IBRX 3
- VYX 7
- Target Price
- IBRX $13.58
- VYX $16.33
- AVG Volume (30 Days)
- IBRX 6.3M
- VYX 1.3M
- Earning Date
- IBRX 11-12-2024
- VYX 02-27-2025
- Dividend Yield
- IBRX N/A
- VYX N/A
- EPS Growth
- IBRX N/A
- VYX N/A
- EPS
- IBRX N/A
- VYX 4.40
- Revenue
- IBRX $7,332,000.00
- VYX $3,592,000,000.00
- Revenue This Year
- IBRX $2,515.60
- VYX N/A
- Revenue Next Year
- IBRX $766.19
- VYX N/A
- P/E Ratio
- IBRX N/A
- VYX $3.01
- Revenue Growth
- IBRX 1218.71
- VYX 956.47
- 52 Week Low
- IBRX $2.28
- VYX $10.87
- 52 Week High
- IBRX $10.53
- VYX $15.98
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- VYX 38.96
- Support Level
- IBRX $2.28
- VYX $12.74
- Resistance Level
- IBRX $2.54
- VYX $13.59
- Average True Range (ATR)
- IBRX 0.25
- VYX 0.44
- MACD
- IBRX 0.10
- VYX -0.07
- Stochastic Oscillator
- IBRX 64.71
- VYX 21.47
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.